Evaluation of TeleOphthalmology in AMD-TeleMedicine Solutions to Improve Patient Access and Quality of Vision Outcomes
Recruitment status was Recruiting
The use of teleophthalmology for patient screening will result in more rapid patient access for treatment. The use of teleophthalmology to monitor patients with wet AMD post-treatment will result in maintenance of good visual outcomes combined with a reduction in patient travel and improved patients satisfaction in a cost effective manner.
The Evaluation of Teleophthalmology in AMD project objectives are as follows:
- To evaluate the efficacy of teleophthalmology in screening patients referred to retina specialists for suspected wet AMD.
- To compare the "time to treatment/retreatment" with this program with that of patient's entering the system and being followed conventionally to determine the efficacy of teleophthalmology to provide rapid entry/re-entry into treatment programs.
- To determine the efficacy of teleophthalmology in monitoring patients with wet AMD post therapy.
- To determine the compliance rate for monitoring wet AMD during follow-up utilizing teleophthalmology.
- To evaluate the cost effectiveness of teleophthalmology in screening/monitoring wet AMD patients including direct costs to the OHIP system and indirect costs to the patient/caregiver.
- To assess patient satisfaction with teleophthalmology versus standard clinical care in the monitoring of post-treatment wet AMD.
- To evaluate teleophthalmology as a tool for communication between community based Optometrists /Ophthalmologists and Retina Specialists.
Age Related Macular Degeneration
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Evaluation of TeleOphthalmology in Age-related Macular Degeneration (AMD) - TeleMedicine Solutions to Improve Patient Access and Quality of Vision Outcomes.|
- Wait time for treatment (naive versus follow-up patients). [ Time Frame: One month for Tele-screening evaluation in both groups. ] [ Designated as safety issue: No ]
- Patient satisfaction. [ Time Frame: One month. ] [ Designated as safety issue: No ]
|Study Start Date:||November 2011|
|Estimated Study Completion Date:||November 2013|
|Estimated Primary Completion Date:||November 2012 (Final data collection date for primary outcome measure)|
Group 1R and 1T AMD Screening
Group 1 patients will be collected through all referrals to any of the physician investigators with a provisional diagnosis of possible wet AMD. Any request for clinical evaluation of a patient for presumed wet AMD will be randomized into Group 1R (Routine Screening) and Group 1T (Tele-ophthalmology screening).
Group 2R and 2T Follow up
Group 2 patients will be collected from the patients previously treated for wet AMD within the practices of the physician investigators. All patients in whom the disease is inactive (not receiving active treatment) and who therefore require monitoring will be randomized into Group 2R (Routine Monitoring) and Group 2T (Teleophthalmology Monitoring).
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01581606
|Contact: Thomas G Sheidow, MD, FRCSCfirstname.lastname@example.org|
|Contact: Anne-Marie Powell, RN||519.685.8500 ext email@example.com|
|Ivey Eye Institute, St. Joseph's Health Care||Recruiting|
|London, Ontario, Canada, N6A 4V2|
|Contact: Thomas G Sheidow, MD, FRCSC 519.685.8133 firstname.lastname@example.org|
|Contact: Anne-Marie Powell, RN 519.685.8500 ext 52606 email@example.com|
|Principal Investigator: Thomas G Sheidow, MD, FRCSC|
|Sub-Investigator: Philip L Hooper, MD, FRCSC|
|Principal Investigator:||Thomas G Sheidow, MD, FRCSC||Ivey Eye Institute, St. Joseph's Health Care, London, Ontario, Canada|